Navigation Links
Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
Date:1/7/2009

SAN DIEGO, Jan. 7 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen-therapeutic agents, today announced a company restructuring that includes the addition of four key leadership positions and a significant reduction in work force, primarily in the product manufacturing area. This restructuring reduces the company's burn rate and refocuses Sangart's business units on pursuing further clinical trials for its lead product, Hemospan(R).

"Sangart remains committed to developing a safe and effective oxygen-therapeutic agent," said Brian O'Callaghan, President and Chief Executive Officer of Sangart. "Our recent successful Phase III clinical studies of Hemospan demonstrated very encouraging efficacy results for the prevention and treatment of hypotension in hip replacement procedures. These trials provide a platform from which to conduct the pivotal clinical studies that will be necessary to establish the clinical benefit of treating patients with Hemospan. The appointment of key executives and the decision to reduce our workforce, which was difficult but necessary, will enable us to focus our resources on these upcoming clinical trials."

As part of the restructuring, Sangart announced appointments for four new leadership positions:

    -- Howard Levy MD, PhD, Chief Scientific Officer -- Dr. Levy will assume
       overall responsibility for preclinical, clinical research, and research
       and development for Hemospan.  A critical care and pulmonary physician,
       Dr. Levy brings more than 20 years of experience both serving as a
       principal investigator at research institutions as well as leading
       clinical study development teams for pharmaceutical companies. Prior to
       Sangart, he was responsible for clinical research of the hemostasis
       platform at Novo Nordisk, Inc.

    -
'/>"/>
SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
2. Aisling Capital Announces Close of US$650M Life Sciences Fund
3. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
4. ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
5. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
6. Horizon Therapeutics Announces Senior Management Appointments
7. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
8. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
9. ADVENTRX Announces Further Cost-Cutting Measures
10. Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project
11. West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... , April 27, 2015  For about a ... is their ability to utilize and catabolize glucose ... cancer cells is called the ,Warburg phenomenon", that ... of high oxygen presence, leading to enhanced lactate ... cells still choose glucose fermentation. A variety of ...
(Date:4/27/2015)... Diego, Calif. (PRWEB) April 27, 2015 ... of drug and chemical toxicity carries implications for advancing ... speaker April 28 at National University , the ... and presentation by Dr. Hanzlik, a professor at the ... drug metabolism and drug design, starts at 5 p.m. ...
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... International Daleco Corporation (Pink Sheets: ILDO) announces its ... joint venture company, ICAP Bio Organic, S. de R.L. ... and proprietary bio-organic catalyst compositions (BOCs) within Central America, Mexico ... renewable energy credit opportunities where available. , SIF ICAP ...
... , BEIJING, Oct. 27 /PRNewswire-Asia/ ... provider of biopharmaceutical products in China, announced today that,it ... vaccine, PANFLU.1, from,China,s Ministry of Industry and Information Technology ... is required to produce an,additional 5.19 million doses of ...
... YORK, Oct. 26 Reportlinker.com announces ... is available in its catalogue. , ... Pipeline Analysis and Competitive Assessment ... , In the nearly 35 ...
Cached Biology Technology:Bio-Organic Catalyst, Inc. Forms Joint Venture With SIF ICAP Mexico S.A. de C.V. as Exclusive Distribution Hub for Central America, Mexico and Caribbean. 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 2Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 4Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 5Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 6Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 7Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 8
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... MIAMI -- The ability of marine reserves to replenish ... their ability to benefit shallow-water communities to thrive remains ... of Miami (UM) Rosenstiel School of Marine & Atmospheric ... has translated into positive impacts on coral communities in ...
... Industries LLC announced today that Oligonol, manufactured by Amino ... a recipient of the SupplySide West 2011 Scientific Excellent ... on Wednesday, October 12, 2011 in Las Vegas at ... technology providers with new ingredients or technologies, as well ...
... fish,s personality may determine how it is captured. This ... evolutionary and ecological consequences for affected fish populations, as ... Anglers fishing near rocky outcrops or in areas of ... catch timid fish, while those fishing in open water ...
Cached Biology News: New study of Glover's Reef challenges whether corals will benefit from Marine Reserves' protection 2Oligonol receives Supplyside West 2011 scientific Excellence Award 2
TUNEL Apoptosis Detection Kit...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Mouse Axl MAb (Clone 175128)...
Biology Products: